You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Prevention of Venous Thromboembolism in Hospitalized Patients With Inflammatory Bowel Disease

Chande, Nilesh MD

Inflammatory Bowel Diseases:
doi: 10.1097/MIB.0b013e31827e7a0f
Cochrane Review
Abstract

Abstract: Venous thromboembolism is a relatively common and potentially serious complication in inpatients with inflammatory bowel disease (IBD). There are a number of pathophysiologic mechanisms for venous thromboembolism that are specific to patients with IBD that may be active. The use of anticoagulants for prophylaxis against venous thromboembolism in hospitalized patients with IBD needs to be balanced against the potential for worsening of rectal bleeding. Evidence from randomized trials suggests that heparin and low–molecular weight heparin are generally safe to use in patients with active IBD, and a number of guidelines support their use for thromboprophylaxis in this patient population.

In Brief

Article first published online 4 February 2013

Author Information

Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, Canada.

Reprints: Nilesh Chande, MD, Room E1-423A, London Health Sciences Centre, Victoria Hospital, 800 Commissioners Road East, London, Ontario, Canada (e-mail: nilesh.chande@lhsc.on.ca).

The author has no financial or conflicts of interest to disclose.

Received June 02, 2012

Accepted June 12, 2012

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.